1. Home
  2. PLSE vs SRPT Comparison

PLSE vs SRPT Comparison

Compare PLSE & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulse Biosciences Inc (DE)

PLSE

Pulse Biosciences Inc (DE)

HOLD

Current Price

$35.13

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Sarepta Therapeutics Inc. (DE)

SRPT

Sarepta Therapeutics Inc. (DE)

HOLD

Current Price

$15.00

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLSE
SRPT
Founded
2014
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.0B
IPO Year
2015
2000

Fundamental Metrics

Financial Performance
Metric
PLSE
SRPT
Price
$35.13
$15.00
Analyst Decision
Buy
Hold
Analyst Count
1
29
Target Price
$22.00
$25.85
AVG Volume (30 Days)
339.2K
3.0M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.88
Revenue
N/A
$2,198,237,000.00
Revenue This Year
$840.00
N/A
Revenue Next Year
$287.54
N/A
P/E Ratio
N/A
$5.42
Revenue Growth
N/A
15.58
52 Week Low
$12.56
$14.68
52 Week High
$36.79
$25.32

Technical Indicators

Market Signals
Indicator
PLSE
SRPT
Relative Strength Index (RSI) 68.96 32.80
Support Level $24.27 N/A
Resistance Level N/A $18.16
Average True Range (ATR) 2.50 0.80
MACD 0.62 -0.24
Stochastic Oscillator 89.49 1.16

Price Performance

Historical Comparison
PLSE
SRPT

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Share on Social Networks: